NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
Patients with metastatic non-squamous NSCLC pre-treated with platinum-doublet chemotherapy and ICI (for those with targetable oncogenic drivers, pretreated with at least one tyrosine kinase inhibitor and platinum-doublet chemotherapy), and active BM, defined as asymptomatic untreated or unequivocally progressive after local treatment
1 total trials1 recruiting
Filter these 1 trials by phase, country, sponsor and more.